Uploaded June 2025 | Updated September 2026, 2 weeks ago
Join me for an in-depth conversation with Cathy O’Hare, Head of Operations at NewLimit, a pioneering biotech company focused on extending human healthspan through epigenetic reprogramming. We discuss NewLimit’s approach to partial reprogramming, the search for rejuvenating transcription factors, and the challenges of translating this science into real-world therapies. Whether you’re a scientist, longevity enthusiast, or curious about biotech’s role in aging, this interview is packed with insights!
Topics Covered:
What is NewLimit and its mission?
The science of partial reprogramming
How NewLimit screens for rejuvenating transcription factors
Use of AI and machine learning in discovery
mRNA delivery and why gene therapy isn’t used
Preclinical models and the road to the clinic
The future of longevity biotech
Find me on Twitter - twitter.com/EleanorSheekey
Support the channel
through PayPal - paypal.me/sheekeyscience?country.x=GB&locale.x=en_GB
through Patreon - patreon.com/TheSheekeyScienceShow
Timestamps
00:00 – Introduction & NewLimit’s Mission
01:06 – Cathy O’Hare’s Background & Role
02:42 – Why Target Cellular Aging?
03:11 – What Is Partial Reprogramming?
05:08 – How NewLimit Screens for Rejuvenating Transcription Factors
08:40 – Machine Learning and Scaling the Discovery Platform
10:07 – Why Use mRNA and Lipid Nanoparticles (LNPs)?
13:51 – Single vs. Combination Transcription Factor Therapies
17:12 – Humanized Mouse Models for In Vivo Screening
21:03 – Roadmap: From Preclinical Models to Clinical Trials
Please note that The Sheekey Science Show is distinct from Eleanor Sheekey's teaching and research roles at the University of Cambridge. The information provided in this show is not medical advice, nor should it be taken or applied as a replacement for medical advice. The Sheekey Science Show and guests assume no liability for the application of the information discussed.
Icons in intro; "freepik.com/free-photos-vectors/background"Background vector created by freepik - freepik.com
Join me for an in-depth conversation with Cathy O’Hare, Head of Operations at NewLimit, a pioneering biotech company focused on extending human healthspan through epigenetic reprogramming. We discuss NewLimit’s approach to partial reprogramming, the search for rejuvenating transcription factors, and the challenges of translating this science into real-world therapies. Whether you’re a scientist, longevity enthusiast, or curious about biotech’s role in aging, this interview is packed with insights!
Topics Covered:
What is NewLimit and its mission?
The science of partial reprogramming
How NewLimit screens for rejuvenating transcription factors
Use of AI and machine learning in discovery
mRNA delivery and why gene therapy isn’t used
Preclinical models and the road to the clinic
The future of longevity biotech
Find me on Twitter - twitter.com/EleanorSheekey
Support the channel
through PayPal - paypal.me/sheekeyscience?country.x=GB&locale.x=en_GB
through Patreon - patreon.com/TheSheekeyScienceShow
Timestamps
00:00 – Introduction & NewLimit’s Mission
01:06 – Cathy O’Hare’s Background & Role
02:42 – Why Target Cellular Aging?
03:11 – What Is Partial Reprogramming?
05:08 – How NewLimit Screens for Rejuvenating Transcription Factors
08:40 – Machine Learning and Scaling the Discovery Platform
10:07 – Why Use mRNA and Lipid Nanoparticles (LNPs)?
13:51 – Single vs. Combination Transcription Factor Therapies
17:12 – Humanized Mouse Models for In Vivo Screening
21:03 – Roadmap: From Preclinical Models to Clinical Trials
Please note that The Sheekey Science Show is distinct from Eleanor Sheekey's teaching and research roles at the University of Cambridge. The information provided in this show is not medical advice, nor should it be taken or applied as a replacement for medical advice. The Sheekey Science Show and guests assume no liability for the application of the information discussed.
Icons in intro; "freepik.com/free-photos-vectors/background"Background vector created by freepik - freepik.com
